Project 2 will use biophysical and structural biology techniques to study the conformation, stability, morphology, and ultrastructure of Immunoglobulin (Ig) light chain proteins (LCs). Igs are over-produced in a variety of B-cell immmunoproliferative diseases, including multiple myeloma and primary amyloidosis (AL). PORTIONS OF Igs-THE LC or its sub-domains-are found in pathological organ deposits, and are also excreted n urine. This is often the first sign of disease. Despite a vast knowledge of PC primary sequence information, the specific features which lead to LC conformational instability and clinical pathology are undefined. We will combine biophysical and ultrastructural studies with the significant resources and proteins available from Projects and Cores of this Program Project, and vast literature on LC primary sequences and known mutations, to systematically investigate the biophysical properties of LCs to precisely define the molecular mechanism of LC fibrillogenesis in AL. Project 2 will test the hypothesis that LC deposition occurs as a result of amino acid substitutions in critical regions of the LC, destabilizing them, promoting insolubility, and aggregation, producing organ damage and death.
The Specific Aims are to investigate the biophysical properties of LCs for their stability and instability under controlled conditions of temperature, pH, ionic strength and protein concentration. Circular dichroism, fluorescence, and high resolution calorimetry will be used to study the conformation, thermodynamic, and thermal stability of LCs. Light, negative stain and cryo-electron microscopy (as appropriate) will be used to study the morphology and structure of LC deposits and AL fibrils. Chromatographic and spectroscopic studies will be performed to monitor monomer-to-aggregate conversion. Protein crystallization, x-ray crystallography and model building will define the sites of structural alteration in amyloidogenic LCs and sub-domains. Basic protein primary sequence information derived in Project 2 will allow design and expression of new proteins in Project 1 for additional studies in this Project. LC instability will be correlated with disease severity, allowing the design of therapies to retard specific steps in the pathway, or prevent deposition completely.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
1P01HL068705-01
Application #
6590081
Study Section
Heart, Lung, and Blood Initial Review Group (HLBP)
Project Start
2002-04-12
Project End
2007-03-31
Budget Start
2002-04-12
Budget End
2003-03-31
Support Year
1
Fiscal Year
2002
Total Cost
$247,748
Indirect Cost
Name
Boston University
Department
Type
DUNS #
604483045
City
Boston
State
MA
Country
United States
Zip Code
02118
Brumshtein, Boris; Esswein, Shannon R; Sawaya, Michael R et al. (2018) Identification of two principal amyloid-driving segments in variable domains of Ig light chains in systemic light-chain amyloidosis. J Biol Chem 293:19659-19671
Sanchorawala, Vaishali; McCausland, Kristen L; White, Michelle K et al. (2017) A longitudinal evaluation of health-related quality of life in patients with AL amyloidosis: associations with health outcomes over time. Br J Haematol 179:461-470
Dasari, Surendra; Theis, Jason D; Vrana, Julie A et al. (2015) Proteomic detection of immunoglobulin light chain variable region peptides from amyloidosis patient biopsies. J Proteome Res 14:1957-67
Cowan, Andrew J; Skinner, Martha; Seldin, David C et al. (2013) Amyloidosis of the gastrointestinal tract: a 13-year, single-center, referral experience. Haematologica 98:141-6
Cowan, Andrew J; Seldin, David C; Skinner, Martha et al. (2012) Amyloid deposits in the bone marrow of patients with immunoglobulin light chain amyloidosis do not impact stem cell mobilization or engraftment. Biol Blood Marrow Transplant 18:1935-8
Flies, Amanda; Ahmadi, Tahamtan; Parks, Ashley J et al. (2012) Immunoglobulin light chain, Blimp-1 and cytochrome P4501B1 peptides as potential vaccines for AL amyloidosis. Immunol Cell Biol 90:528-39
Hovey, B M; Ward, J E; Soo Hoo, P et al. (2011) Preclinical development of siRNA therapeutics for AL amyloidosis. Gene Ther 18:1150-6
Specter, Richard; Sanchorawala, Vaishali; Seldin, David C et al. (2011) Kidney dysfunction during lenalidomide treatment for AL amyloidosis. Nephrol Dial Transplant 26:881-6
Meier-Ewert, H K; Sanchorawala, V; Berk, J et al. (2011) Regression of cardiac wall thickness following chemotherapy and stem cell transplantation for light chain (AL) amyloidosis. Amyloid 18 Suppl 1:130-1
Charlot, Marjory; Seldin, David C; O'hara, Carl et al. (2011) Localized amyloidosis of the breast: a case series. Amyloid 18:72-5

Showing the most recent 10 out of 66 publications